Hsa-miR-483-5p/mRNA network that regulates chemotherapy resistance in locally advanced rectal cancer identified through plasma exosome transcriptomics

doi:10.5306/wjco.v15.i8.1061

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 8

This Article

(133)

(126)

(0)

(45)

(3397)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical and Translational Research

World J Clin Oncol. Aug 24, 2024; 15(8): 1061-1077
Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.1061

Full Size Figure Download Figure

Figure 6 The relationship of the 9 target genes and drug-sensitivity of oxaliplatin. The results indicated that the lower expression of target genes of RNF165, ZNF417, and MAPK3 are prone to exhibit relatively lower IC₅₀ value.

Citation: Li GB, Shi WK, Zhang X, Qiu XY, Lin GL. Hsa-miR-483-5p/mRNA network that regulates chemotherapy resistance in locally advanced rectal cancer identified through plasma exosome transcriptomics. World J Clin Oncol 2024; 15(8): 1061-1077
URL: https://www.wjgnet.com/2218-4333/full/v15/i8/1061.htm
DOI: https://dx.doi.org/10.5306/wjco.v15.i8.1061

Li GB, Shi WK, Zhang X, Qiu XY, Lin GL. Hsa-miR-483-5p/mRNA network that regulates chemotherapy resistance in locally advanced rectal cancer identified through plasma exosome transcriptomics. World J Clin Oncol 2024; 15(8): 1061-1077 [PMID: 39193162 DOI: 10.5306/wjco.v15.i8.1061]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.